Expert Pitch
University of Redlands

Following ethical principles in times of wealth and social tranquility is easy. But take the same ethical principles and drop them into a time of scarcity and panic, and the world looks very different, says University of Redlands professor.

15-May-2020 5:30 AM EDT, by University of Redlands

Riaz Tejani is an associate professor of business ethics at the University of Redlands who can comment on ethical business issues rising out of the pandemic.  

"Following ethical principles in times of wealth and social tranquility is easy. People share, businesses honor employees and customers, and governments balance growth with sustainability. But take the same ethical principles and drop them into a time of scarcity and panic, and the world looks very different.  

"The COVID-19 global public health emergency has demonstrated this all too well for a new generation to cringe and learn. Determining 'the right thing to do' has gotten much harder now. Do you keep your business open to serve the public or shutter to protect employees? Do you raise prices on necessities or keep them low to allow easy access—knowing all the while that hoarders will themselves 'buy low and sell high.' And if you’re a member of the United States Senate in possession of early intelligence briefings, do you sell your personal stockholding because you know, before most Americans, that the whole economy is about to plummet?  

"Facing us with such questions like never before, COVID-19 is both a scourge and an opportunity. It is a scourge not only because it is hurting and killing, but because it is doing so to people in near-total isolation from families, friends, communities, and society. Once diagnosed or suspected of having the disease, we are atomized, severed from loved ones and visitors in a way that defies human tendencies to need empathy and care. But it is an opportunity for leaders and organizations to reflect on their values—on the ways that they once construed 'the right thing to do.'

"While the disaster proves to be a moment for ethical self-examination, and one would hope it is used to full advantage, it is probably only the latest in a string of epochal events that include the 2008 financial crisis, and the 2001 9/11 attacks. When it comes to corporate ethics in times of global crisis, we are seeing yet again that heroes aren’t made they are born—and sadly not very often."   

Biography :
Riaz Tejani is an associate professor of business ethics. His research examines problems in legal and business ethics with a focus on race and class inequality, access to justice, and higher education. Riaz's first book, Law Mart: Justice, Access, and For-Profit Law Schools (2017), is an ethnographic account of for-profit legal education during and after the global financial crisis. His second book, Law and Society Today, critically surveys contemporary themes in socio-legal studies after "law and economics". Riaz serves on the National Advisory Council of the non-profit research center Law School Transparency, and his recent articles have appeared in American Ethnologist, U.C. Irvine Law Review, and Political and Legal Anthropology Review. His work has been cited or reviewed in outlets including the Harvard Law Review, Yale Law Journal Forum, Annual Review of Law and Social Science, The Nation, Huffington Post, Salon, and NPR.




Filters close

Showing results

110 of 2539
Released: 13-Jul-2020 4:05 PM EDT
OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available
Organization for Associate Degree Nursing (OADN)

OADN & AACN Secure No-Cost Access to COVID-19 Screening Solution Until Vaccines Become Widely Available

Newswise: Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Released: 13-Jul-2020 3:45 PM EDT
Study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe COVID-19 infection
Hackensack Meridian Health

The mechanisms of action of acalabrutinib led to the hypothesis it might be effective in reducing the massive inflammatory response seen severe forms of COVID19. Indeed, it did provide clinical benefit in a small group of patients by reducing their inflammatory parameters and improving their oxygenation.

Newswise: National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Released: 13-Jul-2020 3:40 PM EDT
National Virtual Biotechnology Laboratory Unites DOE Labs Against COVID-19
Department of Energy, Office of Science

To focus its efforts against the COVID-19 pandemic, DOE is bringing the national laboratories together into the National Virtual Biotechnology Laboratory.

Newswise: Key Insights from Swedish Casino that Remained Open During COVID-19
Released: 13-Jul-2020 3:40 PM EDT
Key Insights from Swedish Casino that Remained Open During COVID-19
University of Nevada, Las Vegas (UNLV)

As casinos in Las Vegas enter the second month of reopening since the COVID-19 pandemic took hold, UNLV gaming researchers say they can draw upon insights from industry collaborators in Sweden, a country that took a more open approach to the crisis compared to other governments.

Released: 13-Jul-2020 3:05 PM EDT
Asymptomatic Transmission and Reinfection of COVID: Live Event for July 16, 2PM EDT
Newswise

Emerging data shows more risk of asymptomatic transmission and reinfection with COVID than previously thought. Experts will discuss these findings and what are the implications for managing the pandemic. Media are invited to attend and ask questions.

Released: 13-Jul-2020 2:40 PM EDT
Engineered llama antibodies neutralize COVID-19 virus
Rosalind Franklin Institute

Antibodies derived from llamas have been shown to neutralise the SARS-CoV-2 virus in lab tests, UK researchers announced today.

Released: 13-Jul-2020 1:25 PM EDT
1 in 3 young adults may face severe COVID-19
University of California, San Francisco (UCSF)

As the number of young adults infected with the coronavirus surges throughout the nation, a new study by researchers at UCSF Benioff Children's Hospitals indicates that youth may not shield people from serious disease.

Released: 13-Jul-2020 12:25 PM EDT
Scientists discover key element of strong antibody response to COVID-19
Scripps Research Institute

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

Released: 13-Jul-2020 11:15 AM EDT
UTHealth joins study of blood pressure medication’s effect on improving COVID-19 outcomes
University of Texas Health Science Center at Houston

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.


Showing results

110 of 2539

close
4.2494